Abstract
The use of magnetic micro- and nano-particles as carriers for in vivo targeting of therapeutic compounds was first proposed over 25 years ago. Since then, a variety of animal studies have demonstrated the efficacy of the technique, however, only a handful of Phase I/II clinical trials have taken place. While the theoretical underpinnings have been lacking, recent advances in mathematical modeling of magnetic targeting, as well as the development of novel magnetic nanoparticle carriers and implantable magnets, show promise in progressing this technology from the laboratory to the clinic.